Immunic, Inc. Common Stock
Symbol: IMUX (NASDAQ)
0.88
▲ (2.53%) 0.022
Company Description:
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Key Stats
- Today's Open: $0.87
- Today's High: $0.919
- Today's Low: $0.857
- Today's Volume: 1.01M
- Yesterday Close: $0.8573
- Yesterday High: $0.8719
- Yesterday Low: $0.8223
- Yesterday Volume: 1.16M
- Last Min Volume: 790
- Last Min High: $0.879
- Last Min Low: $0.879
- Last Min VWAP: $0.879
Company Profile
- Name: Immunic, Inc. Common Stock
- Website: https://www.imux.com
- Listed Date: 2014-04-17
- Location: NEW YORK, X1
- Market Status: Active
- CIK Number: 0001280776
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $81.55M
- Round Lot: 100
- Outstanding Shares: 98.65M
- Asset Type: CS
RECENT FILINGS FOR IMUX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-27 | S-8 | View |
| 2025-08-14 | SCHEDULE 13G | View |
| 2025-08-14 | SCHEDULE 13G | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-08-08 | SCHEDULE 13G | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-31 | SCHEDULE 13G | View |
| 2025-07-18 | 4 | View |
| 2025-07-18 | 4 | View |
| 2025-07-18 | 4 | View |
| 2025-07-18 | 4 | View |
| 2025-07-18 | 4 | View |
| 2025-07-11 | 8-K | View |
| 2025-06-27 | 8-K | View |
| 2025-06-20 | 4/A | View |
| 2025-06-20 | 4/A | View |
| 2025-06-20 | 4/A | View |
Latest News on IMUX